Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AstraZeneca Agrees To Limit Distribution, Promotion Of Crestor 40 Mg

Executive Summary

AstraZeneca has agreed to an unusual distribution system for Crestor to limit use of the 40 mg dose of the statin

You may also be interested in...



Crestor DTC Ads To Resume Following Safety Labeling Update

AstraZeneca will resume direct-to-consumer ads for Crestor following the completion of labeling revisions that emphasize an increased risk of rhabdomyolysis, especially at the statin's highest approved dose

Crestor DTC Ads To Resume Following Safety Labeling Update

AstraZeneca will resume direct-to-consumer ads for Crestor following the completion of labeling revisions that emphasize an increased risk of rhabdomyolysis, especially at the statin's highest approved dose

AstraZeneca Crestor Defense Minimizes Risk Of High Dose, FDA Says

An AstraZeneca newspaper ad defending the safety of Crestor improperly suggests that all doses of rosuvastatin are "just as safe" as other statins, FDA says in a Dec. 21 "untitled" letter to the company

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS042306

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel